Related Experiment Video
Updated: Oct 3, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Interaction between metabotropic and NMDA glutamate receptors in the periaqueductal grey pain modulatory system
1Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Faculty of Medicine and Surgery, Second University of Naples, Via Costantinopoli 16, 80138 Naples, Italy.
Abstract:
The formalin test was used to investigate the interactive role of periaqueductal grey (PAG) N-methyl-D-aspartate (NMDA) and metabotropic glutamate (mGlu) receptors in the modulation of persistent noxious stimulation in mice. Intra-PAG microinjections of 1 or 3 nmol NMDA, a selective agonist at NMDA-subtype receptors, decreased the nociceptive response (-94+/-5% with 3 nmol) during the latter phase of the test. This effect was antagonized by MK-801, a selective antagonist at NMDA receptors. No change in the early nociceptive phase was observed after NMDA injection. Pretreatment either with 2-methyl-6-phenylethynylpyridine (MPEP, 25 nmol/mouse), a selective antagonist at mGlu5 receptors, or with (2S)-alpha-ethylglutamic acid [(2S)-alpha-EGlu, 30 nmol/mouse], a selective antagonist at group-II mGluRs, prevented the NMDA-induced antinociceptive effect during the late hyperalgesic phase. Pretreatment with (R,S)-alpha-methylserine-O-phosphate [(R,S)-alpha-MSOP, 70 nmol/mouse], a selective antagonist at group-III mGlu receptors, had no effect on the NMDA-induced antinociception. None of the antagonists changed the formalin-induced nociceptive behaviour per se with the dosages used in combination with NMDA. MPEP at 50 nmol/mouse, however, potentiated the early nociceptive phase whilst 100 nmol/mouse attenuated the late phase. Similarly, at the higher dose of 140 nmol/mouse, (R,S)-alpha-MSOP decreased the late hyperalgesic phase. These results provide additional evidence that NMDA and mGlu receptors participate in modulating the hyperalgesia induced by peripheral noxious stimulation. In particular, mGlu receptors may modulate the NMDA receptors in the PAG since their physiological stimulation seems to be required for the NMDA-induced effect. This suggests that, together with ionotropic glutamate receptors, mGlu receptors also play a role in modulating a type of spinal cord neuroplasticity (i.e. wind-up) that has been proposed to mediate hyperalgesia.
Insights
Periaqueductal grey (PAG) N-methyl-D-aspartate (NMDA) receptors modulate pain, but require metabotropic glutamate (mGlu) receptors for their antinociceptive effect. This suggests mGlu receptors are key in pain modulation pathways.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- The periaqueductal grey (PAG) plays a crucial role in pain modulation.
- N-methyl-D-aspartate (NMDA) and metabotropic glutamate (mGlu) receptors are implicated in nociception.
Purpose of the Study:
- To investigate the interactive roles of PAG NMDA and mGlu receptors in modulating persistent pain.
- To determine the specific roles of different mGlu receptor subtypes (mGlu5, group II, group III) in NMDA-mediated antinociception.
Main Methods:
- The formalin test was employed in mice to assess nociceptive responses.
- Microinjections of NMDA and various mGlu receptor antagonists (MPEP, (2S)-alpha-EGlu, (R,S)-alpha-MSOP) were administered into the PAG.
- The effects of these agents on early and late nociceptive phases were analyzed.
Main Results:
- Intra-PAG NMDA administration significantly reduced nociception during the late phase of the formalin test.
- NMDA-induced antinociception was blocked by NMDA receptor antagonist MK-801.
- Antagonists for mGlu5 and group II mGlu receptors, but not group III, prevented the NMDA-induced antinociceptive effect.
- Specific mGlu receptor antagonists alone had differential effects on nociceptive phases at higher doses.
Conclusions:
- NMDA and mGlu receptors in the PAG are critical for modulating hyperalgesia induced by noxious stimuli.
- Metabotropic glutamate receptors appear to modulate NMDA receptor function in the PAG, suggesting a role in pain processing.
- These findings highlight the potential of targeting mGlu receptors, alongside ionotropic glutamate receptors, for managing chronic pain conditions involving spinal cord neuroplasticity like wind-up.
Related Concept Videos
Analgesia and Pain Management
Nociception
Opioid Receptors: Overview
Pain
Ligand-Gated Ion Channel Receptor: Gating Mechanism
